Mendaera vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 35)
Mendaera logo

Mendaera

EmergingHealthcare

AI-Guided Robotic Systems for Minimally Invasive Procedures

Mendaera is developing robotic systems that combine real-time imaging and AI guidance to enable minimally invasive procedures with greater precision and speed; raised $100M in a 2024 Series B led by GV and Bessemer;

AI VisibilityBeta
Overall Score
D35
Category Rank
#569 of 596
AI Consensus
69%
Trend
stable
Per Platform
ChatGPT
34
Perplexity
35
Gemini
29

About

Mendaera is a San Francisco-based medical technology company developing a new class of robotic systems designed to make minimally invasive procedures faster, more precise, and more accessible across a broader range of clinical settings. The company's platform integrates real-time imaging — including ultrasound and CT fluoroscopy — with AI-powered guidance and robotic actuation to assist clinicians performing needle-based interventions such as biopsies, fluid drainage, nerve blocks, and targeted drug delivery. By automating the most technically demanding aspects of needle placement, Mendaera's system aims to reduce procedure time, decrease complication rates, and enable procedures to be performed at the bedside or in community hospitals rather than exclusively in specialized interventional suites.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
up
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

35
Overall Score
93
#569
Category Rank
#1
69
AI Consensus
80
stable
Trend
up
34
ChatGPT
94
35
Perplexity
89
29
Gemini
94
41
Claude
92
41
Grok
98

Key Details

Category
AI-Guided Robotic Systems for Minimally Invasive Procedures
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.